OBJECTIVES: Report baseline patient characteristics of the CAMPOS study, which is evaluating the PMO care map in Swiss clinical practice.  METHODS: Between June 2012„ŸMay 2013, specialist osteoporosis centers operating a DXA machine enrolled women diagnosed with PMO who initiated intravenous (IV) ibandronate or zolendronate, or subcutaneous (SC) denosumab (index date) within 6 months prior to center initiation. Study outcomes are recorded at index date (baseline) and any visit in the 24-month observation period thereafter, as available from routine practice. RESULTS: Twenty-one centers, mainly in urban regions (81%), of a non-academic nature (76%), and specializing in rheumatology (71%), recruited 275 women. Two-hundred-sixty-three met the inclusion criteria and were included in this baseline analysis; 180 (68%) of these received follow-up care at the specialist center and 83 (32%) were referred back to general practice. At baseline, mean (SD) age was 70.9 (9.7) years and mean time since diagnosis 5.4 (5.4) years (n=248). The following diagnostic parameters and risk factors were assessed at the time of PMO diagnosis: prior osteoporotic fracture, 258 [94%] patients, with 60% reporting this risk factor; DXA bone mineral density (BMD) scan, 255 (97%) patients (hip and either lumbar spine or forearm BMD measured in 231 [88%] patients), mean (SD) BMD T-scores at the femoral neck and lumbar spine -2.34 (0.79; n=230) and -2.89 (1.28; n=232), respectively; calcium and vitamin D status, 260 (99%) patients; fracture history, 258 [98%] patients. CONCLUSIONS: In the current study, prevalent fractures were assessed in almost all women initiating IV ibandronate or zolendronate, or SC denosumab, and the majority reported at least one prior fracture. Calcium and vitamin D status, DXA BMD scans and/or fracture history were also routinely assessed at PMO diagnosis.